Sugi Predict

Sugi Predict / Compounds / SCHEMBL321639

SCHEMBL321639

SCHEMBL321639

CCCCCCCCCCCCCCCC(=O)Nc1cc2c(C)cc(=O)oc2cc1O

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 13/20 0.83
▸ KDM4E B2RXH2 12/20 0.83
▸ SMN1; SMN2 Q16637 4/20 0.83
▸ HPGD P15428 9/20 0.62
▸ HSD17B10 Q99714 6/20 0.62
▸ KMT2A Q03164 2/20 0.53
▸ MEN1 O00255 1/20 0.53
▸ MCL1 Q07820 3/20 0.52
▸ CYP3A4 P08684 1/20 0.51
▸ THRB P10828 1/20 0.51
▸ AKR1B1 P15121 1/20 0.51
▸ GAA P10253 4/20 0.49
▸ GLA P06280 2/20 0.49
▸ HTT P42858 2/20 0.48
▸ NCOA3 Q9Y6Q9 1/20 0.48
▸ EP300 Q09472 1/20 0.47
▸ NPC1 O15118 2/20 0.46
▸ RAB9A P51151 2/20 0.46
▸ CASP3 P42574 1/20 0.46
▸ SENP8 Q96LD8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31022581 1.00 ALDH1A1 (0.83) ALDH1A1KDM4ESMN1; SMN2HPGDHSD17B10
SCHEMBL2729633 1.00 ALDH1A1 (0.83) ALDH1A1KDM4ESMN1; SMN2HPGDHSD17B10
SCHEMBL9883099 0.85 KDM4E (0.61) ALDH1A1KDM4ESMN1; SMN2HPGDHSD17B10
SCHEMBL30607190 0.80 KDM4E (0.77) ALDH1A1KDM4ESMN1; SMN2HPGDHSD17B10
SCHEMBL14974877 0.80 KDM4E (0.77) ALDH1A1KDM4ESMN1; SMN2HPGDHSD17B10
SCHEMBL308979 0.80 KDM4E (0.61) ALDH1A1KDM4ESMN1; SMN2HPGDHSD17B10
SCHEMBL2729641 0.79 KDM4E (0.60) ALDH1A1KDM4ESMN1; SMN2HPGDHSD17B10
SCHEMBL12987557 0.79 KDM4E (0.78) ALDH1A1KDM4ESMN1; SMN2HPGDHSD17B10
SCHEMBL29435303 0.79 KDM4E (0.78) ALDH1A1KDM4ESMN1; SMN2HPGDHSD17B10
SCHEMBL14493664 0.78 EP300 (0.56) ALDH1A1KDM4ESMN1; SMN2HPGDTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9513253-B2 Droplet actuators and techniques for droplet-based enzymatic assays ADVANCED LIQUID LOGIC, INC. (US) 2016-12-06 — — US claimed
EP-2516669-B1 ENZYME ASSAYS ON A DROPLET ACTUATOR ADVANCED LIQUID LOGIC INC (US) 2016-10-12 — — EP claimed
US-20140246319-A1 DROPLET ACTUATORS AND TECHNIQUES FOR DROPLET-BASED ASSAYS ADVANCED LIQUID LOGIC, INC. (US) 2014-09-04 — — US claimed
WO-2013009927-A2 DROPLET ACTUATORS AND TECHNIQUES FOR DROPLET-BASED ASSAYS ADVANCED LIQUID LOGIC, INC. (US) 2013-01-17 — — WO claimed
EP-2516669-A2 ENZYME ASSAYS ON A DROPLET ACTUATOR Advanced Liquid Logic, Inc. (US) 2012-10-31 — — EP claimed
US-8093062-B2 Enzymatic assays using umbelliferone substrates with cyclodextrins in droplets in oil NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2012-01-10 — — US claimed
WO-2011084703-A2 ENZYME ASSAYS ON A DROPLET ACTUATOR ADVANCED LIQUID LOGIC, INC. (US) 2011-07-14 — — WO claimed
US-20110118132-A1 Enzymatic Assays Using Umbelliferone Substrates with Cyclodextrins in Droplets of Oil ADVANCED LIQUID LOGIC, INC. (US) 2011-05-19 — — US claimed
US-12571037-B2 Systems and methods using magnetically-responsive sensors for determining a genetic characteristic ILLUMINA, INC. (US) 2026-03-10 — — US disclosed
US-20250381567-A1 MICROFLUIDICS SYSTEM, DEVICE, AND METHODS FOR PERFORMING RAPID POLYMERASE CHAIN REACTION (PCR) PROTOCOLS BAEBIES, INC. (US) 2025-12-18 — — US disclosed
US-20250369869-A1 Microfluidics system, instrument, and cartridge including self-aligning optical fiber system and method NICOYA LIFESCIENCES INC (CA) 2025-12-04 — — US disclosed
EP-4630164-A1 METHODS FOR PERFORMING RAPID POLYMERASE CHAIN REACTION (PCR) PROTOCOLS IN MICROFLUIDICS SYSTEM Baebies, Inc. (US) 2025-10-15 — — EP disclosed
US-12411297-B2 Microfluidics system, instrument, and cartridge including self-aligning optical fiber system and method SWK FUNDING LLC 2025-09-09 — — US disclosed
US-12390813-B2 Microfluidics system, device, and methods for performing rapid polymerase chain reaction (PCR) protocols BAEBIES, INC. (US) 2025-08-19 — — US disclosed
US-8093062-B2 Enzymatic assays using umbelliferone substrates with cyclodextrins in droplets in oil NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2012-01-10 — — US disclosed
WO-2011084703-A2 ENZYME ASSAYS ON A DROPLET ACTUATOR ADVANCED LIQUID LOGIC, INC. (US) 2011-07-14 — — WO disclosed
US-20110118132-A1 Enzymatic Assays Using Umbelliferone Substrates with Cyclodextrins in Droplets of Oil ADVANCED LIQUID LOGIC, INC. (US) 2011-05-19 — — US disclosed
US-20110118132-A1 Enzymatic Assays Using Umbelliferone Substrates with Cyclodextrins in Droplets of Oil ADVANCED LIQUID LOGIC, INC. (US) 2011-05-19 — — US disclosed
WO-2011023624-A1 BISPHOSPHONATES AS INHIBITORS OF ACID SPHINGOMYELINASE HUMBOLDT-UNIVERSITÄT ZU BERLIN (DE) 2011-03-03 — — WO disclosed
EP-2289900-A1 Bisphosphonates as inhibitors of acid sphingomyelinase Humboldt Universität zu Berlin (DE) 2011-03-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12571037-B2 Systems and methods using magnetically-responsive sensors for determining a genetic characteristic ADAR, DHFR, MB ALDH1A1 973/4885KDM4E 3260/4885SMN1; SMN2 2832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.